Sol-Gel Technologies Receivables 2016-2024 | SLGL
Sol-Gel Technologies receivables from 2016 to 2024. Receivables can be defined as the total amount of collectibles for a company
Sol-Gel Technologies Annual Receivables
(Millions of US $) |
| 2023 |
$0 |
| 2022 |
$8 |
| 2021 |
$13 |
| 2020 |
$2 |
| 2019 |
$4 |
| 2018 |
$ |
| 2017 |
$ |
| 2016 |
$ |
| 2015 |
$ |
Sol-Gel Technologies Quarterly Receivables
(Millions of US $) |
| 2024-06-30 |
$6 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$0 |
| 2023-09-30 |
|
| 2023-06-30 |
$2 |
| 2023-03-31 |
$6 |
| 2022-12-31 |
$8 |
| 2022-09-30 |
$11 |
| 2022-06-30 |
$10 |
| 2022-03-31 |
$10 |
| 2021-12-31 |
$13 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$1 |
| 2021-03-31 |
$1 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$2 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
$4 |
| 2019-12-31 |
$4 |
| 2019-09-30 |
$5 |
| 2019-06-30 |
$8 |
| 2019-03-31 |
$6 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.016B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
